Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology PipelineGlobeNewsWire • 05/15/23
Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?Zacks Investment Research • 05/05/23
Here's Why Momentum in Ikena Oncology, Inc. (IKNA) Should Keep goingZacks Investment Research • 05/03/23
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology DaysGlobeNewsWire • 04/20/23
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual MeetingGlobeNewsWire • 04/17/23
Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/14/23
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS TargetingGlobeNewsWire • 03/07/23
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial CarcinomaGlobeNewsWire • 03/06/23
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate UpdateGlobeNewsWire • 11/28/22
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare ConferenceGlobeNewsWire • 11/22/22
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial CarcinomaGlobeNewsWire • 11/10/22
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/22
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/07/22
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 11/07/22
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic ResistanceGlobeNewsWire • 10/26/22
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo PathwayGlobeNewsWire • 10/18/22
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingGlobeNewsWire • 10/05/22
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/11/22
Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/11/22